Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

What does COMPASS mean for vascular surgeons?

Key clinical point: Treatment should consider both the risk of bleeding and the likelihood of ischemic and/or limb risk.

Major finding: COMPASS showed that rivaroxaban 2.5 mg twice daily plus daily aspirin decreases major adverse cardiovascular and cerebrovascular events in peripheral arterial disease.

Study details: COMPASS assessed 7,470 patients with peripheral arterial disease or coronary artery disease; this analysis used two case study examples.

Disclosures: Dr. Hussain reported having no conflicts; his coauthors reported receiving funding from various pharmaceutical companies, including Bayer, which was a sponsor of the original COMPASS trial.

Citation:

Hussain MA et al. Curr Opin Cardiol. 2019;34:178-84.